- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05351931
Role of Antisecretory Factor in Curative Radiochemotherapy for Anal Carcinoma (SALFLAC)
A Randomized Phase 2 Double-blind Placebo-controlled Trial Investigating the Effect of Salovum™ and SPC-flakes on Radiochemotherapy Induced Toxicity in Curative Treatment of Anal Carcinoma
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Curative RCT for AC is associated with considerable acute and long-term toxicity.
The acute toxicity derives from the combined effects of radiation and chemotherapy and is dominated by localized skin mucositis, diarrhoea and pain from radiation and nausea, fatigue, anemia/leukopenia, diarrhoea and general skin dryness from chemotherapy. These adverse effects are treated symptomatically with mostly modest effect and sometimes leads to the need for in-patient care and temporary stop of the RCT. Long-term toxicity is caused by radiation fibrosis and is dominated by impaired anal sphincter function leading to faeces incontinence, pelvic pain and reduced sexual function. Thus, new ways to efficiently counteract the RCT induced adverse effects are urgently needed.
Cholera induced diarrhoea, as well as other forms of diarrhoea-inducing agents, has been shown to elicit a stimulated, endogenous production of a protein, named "antisecretory factor" (ASF). This protein has been chemically characterized in detail. ASF acts by modulating secretion of water and ions but also counteracts inflammatory processes . ASF is also produced by hens fed on a diet of fermented grains or a specific diet of sugars and amino acids, leading to an accumulation of the ASF protein in the egg yolk. Spray dried yolk in the form of a powder is commercialized as Salovum registered by the EU authorities as "Food for specific medical purposes", i e is not adrug from a regulatory perspective.
Salovum rapidly increase the plasma (P-) ASF-concentration. Another way to increase ASF and, thus, to achieve benefit, is to induce its production/conversion by ingestion of oat flakes, specially processed (similar to malting) to contain the proper mix of sugars and amino acids. Such flakes are also commercially available (named SPC flakes) as "Food for specific medical purposes" and has been recommended or considered for a number of secretory pathological conditions, e g for treatment of Mb Meniére.
With this background the present study will investigate if induction of endogenous ASF by intake of SPC-flakes might be beneficial in AC patients to prevent RCT induced adverse events (AEs) and if administration of ASF from Salovum provides additional benefit (explorative).
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Peter Nygren, MD
- Número de teléfono: +46704250719
- Correo electrónico: peter.nygren@igp.uu.se
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age ≥ 18 years.
- Histologically confirmed diagnosis of AC irrespective of tumour p16-status.
- Planned for curative RCT according to national care programme schedule B
- WHO performance status of 0 or 1.
- For patients planned for schedule C, they must be unsuitable for or not consenting to participation in the SWANCA trial.
- Able to understand study information and questionnaires and provide signed informed consent.
Exclusion Criteria:
- Patients with stoma.
- Contraindications to the investigational product, e g known or suspected hypersensitivity to the investigational products or expected inability to their use in accordance with the protocol.
- Contraindications to curative RCT in accordance with AC national care programme.
- Lack of suitability for participation in the study, e g expected difficulties to follow the protocol procedures, as judged by the investigator.
- Prior exposure to Salovum or SPC-flakes.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: SPC-flakes with or without Salovum
SPC-flakes flat dose of 75 g/d divided in 2 - 4 doses started 5 days prior to start of RCT and continued during the RCT.
Salovum egg powder 4 g/sachet.
Four sachets, ie 16 g q 8 h for 5 days prior to start of RCT.
The appropriate amount of Salovum is mixed with 100 - 200 ml of suitable liquid, eg fruit juice, and ingested orally.
|
Salovum and SPC-flakes are foods approved for specific medical purposes.
|
Comparador de placebos: SPC-flakes placebo with or without Salovum placebo
SPC-placebo flat dose of 75 g/d divided in 2 - 4 doses started 5 days prior to start of RCT and continued during the RCT.
Salovum placebo egg powder 4 g/sachet.
Four sachets, ie 16 g q 8 h for 5 days prior to start of RCT.
The appropriate amount of Salovum placebo is mixed with 100 - 200 ml of suitable liquid, eg fruit juice, and ingested orally.
|
Salovum and SPC-flakes are foods approved for specific medical purposes.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Incidence of diarrhoea, fecal urgency, anal skin toxicity/mucositis and anal pain CTCAEv5.0 ≥ grade 2 during and up to 6 months after RCT. Anal skin toxicity/mucositis is to be verified by photos.
Periodo de tiempo: Through study completion, approximately 6 months
|
Treatment related toxicity
|
Through study completion, approximately 6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Incidence and severity of other AEs according to CTCAEv5.0 during and up to 6 months after RCT.
Periodo de tiempo: Through study completion, approximately 6 months
|
Other treatment related toxicity
|
Through study completion, approximately 6 months
|
Change from baseline in patient reported hQoL and abdominal symptoms assessed by EORTC QLQ- 30 and the ANL27 subscale questionnaires as well as the Bristol Stool Form Scale.
Periodo de tiempo: Through study completion, approximately 6 months
|
PROMS
|
Through study completion, approximately 6 months
|
Increase in plasma (P)-ASF concentration from baseline to the day of start of RCT and to the end of treatment.
Periodo de tiempo: Days -1, 6 and 42
|
Pharmacodynamic outcome and compliance check
|
Days -1, 6 and 42
|
Relationships between P-ASF concentration, biomarkers reflecting inflammation and adverse events.
Periodo de tiempo: Through study completion, approximately 6 months
|
Biomarker assessments
|
Through study completion, approximately 6 months
|
Differences in primary and secondary endpoints between Salovum and placebo subgroups.
Periodo de tiempo: Through study completion, approximately 6 months
|
Assessment of added value of Salovum
|
Through study completion, approximately 6 months
|
Tumour response rate according to RECIST v1.1 and clinical examination at 2, 3 (radiology) and 6 months after stop of RCT.
Periodo de tiempo: Through study completion, approximately 6 months
|
Assessment of benefit, if any, from study products on clinical outcome
|
Through study completion, approximately 6 months
|
Disease free and overall survival at 3 and 6 months after stop of RCT.
Periodo de tiempo: At 3 and 6 months after stop of treatment
|
Assessment of benefit, if any, from study products on clinical outcome
|
At 3 and 6 months after stop of treatment
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Incidence of AEs CTCAEv5.0 grade ≥ 2 considered probably related to investigational products/placebo.
Periodo de tiempo: Through study completion, approximately 6 months
|
Adverse effects from study products
|
Through study completion, approximately 6 months
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Ulgheri C, Paganini B, Rossi F. Antisecretory factor as a potential health-promoting molecule in man and animals. Nutr Res Rev. 2010 Dec;23(2):300-13. doi: 10.1017/S0954422410000193. Epub 2010 Aug 5.
- Laurenius A, Wangberg B, Lange S, Jennische E, Lundgren BK, Bosaeus I. Antisecretory factor counteracts secretory diarrhoea of endocrine origin. Clin Nutr. 2003 Dec;22(6):549-52. doi: 10.1016/s0261-5614(03)00057-8.
- Johansson E, Jennische E, Lange S, Lonnroth I. Antisecretory factor suppresses intestinal inflammation and hypersecretion. Gut. 1997 Nov;41(5):642-5. doi: 10.1136/gut.41.5.642.
- Cinausero M, Aprile G, Ermacora P, Basile D, Vitale MG, Fanotto V, Parisi G, Calvetti L, Sonis ST. New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. Front Pharmacol. 2017 Jun 8;8:354. doi: 10.3389/fphar.2017.00354. eCollection 2017.
- Lonnroth I, Lange S. Purification and characterization of the antisecretory factor: a protein in the central nervous system and in the gut which inhibits intestinal hypersecretion induced by cholera toxin. Biochim Biophys Acta. 1986 Aug 6;883(1):138-44. doi: 10.1016/0304-4165(86)90144-3.
- Eriksson A, Shafazand M, Jennische E, Lange S. Effect of antisecretory factor in ulcerative colitis on histological and laborative outcome: a short period clinical trial. Scand J Gastroenterol. 2003 Oct;38(10):1045-9. doi: 10.1080/00365520310005064.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Anticipado)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias
- Neoplasias por sitio
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades intestinales
- Neoplasias Intestinales
- Enfermedades Rectales
- Neoplasias colorrectales
- Neoplasias Rectales
- Enfermedades del Ano
- Neoplasias del Ano
Otros números de identificación del estudio
- ASF 3
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de ano
-
The Cleveland ClinicBard LtdTerminado
-
Hvidovre University HospitalDesconocidoFoco: Incontinencia anal después de esfinterotomía lateral por fisura anal crónicaDinamarca
-
Hospices Civils de LyonTerminado
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminadoCáncer anal en estadio III AJCC v8 | Carcinoma de células escamosas del canal anal | Cáncer anal en estadio IIB AJCC v8 | Cáncer anal en estadio IIIA AJCC v8 | Cáncer anal en estadio IIIB AJCC v8 | Cáncer anal en estadio IIIC AJCC v8 | Cáncer anal en estadio I AJCC v8 | Cáncer anal en estadio II AJCC... y otras condicionesEstados Unidos
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminadoCarcinoma anal de células escamosas | Cáncer anal en estadio III AJCC v8 | Cáncer anal en estadio IIB AJCC v8 | Cáncer anal en estadio IIIA AJCC v8 | Cáncer anal en estadio IIIB AJCC v8 | Cáncer anal en estadio IIIC AJCC v8 | Cáncer anal en estadio I AJCC v8 | Cáncer anal en estadio II AJCC v8 | Cáncer... y otras condicionesEstados Unidos
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Activo, no reclutandoCarcinoma anal de células escamosas | Carcinoma basaloide anal | Carcinoma cloacogénico del canal anal | Carcinoma del canal anal metastásico | Carcinoma del canal anal recidivante | Cáncer del canal anal en estadio IIIB | Cáncer del canal anal en estadio IVEstados Unidos
-
Institut Cancerologie de l'OuestTerminadoCáncer de cuello uterino | Cancer de prostata | Cánceres del canal analFrancia
-
Assaf-Harofeh Medical CenterTerminado
-
University Hospital, Strasbourg, FranceAún no reclutandoLesiones del esfínter analFrancia
-
RDD Pharma LtdTerminado